Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT02362516
PHASE1

Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809

Sponsor: Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

To assess the exposure of BI 425809 in cerebrospinal fluid relative to plasma as well as safety and tolerability, and to evaluate the effect of different doses of BI 425809 on biomarkers levels in cerebrospinal fluid.

Official title: Non-randomised, Open Label, Sequential-group Study to Assess the Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809 in Healthy Male Volunteers

Key Details

Gender

MALE

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

25

Start Date

2015-02-23

Completion Date

2015-06-19

Last Updated

2026-05-01

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

BI 425809

Tablet

Locations (1)

1346.3.32001 Boehringer Ingelheim Investigational Site

Antwerp, Belgium